MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis

Emilie Vallières*, Jacqueline C. Rendall, John E. Moore, John McCaughan, Anne I. Hoeritzauer, Michael M. Tunney, Joseph Stuart Elborn, Damian G. Downey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)
334 Downloads (Pure)


UK cystic fibrosis (CF) guidelines recommend eradication of methicillin-resistant Staphylococcus aureus (MRSA) when cultured from respiratory samples. As there is no clear consensus as to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in our CF centre and long-term clinical outcome. All new MRSA positive sputum cultures (n=37) that occurred between 2000 and 2014 were reviewed. Eradication regimen characteristics and clinical, microbiological and long-term outcome data were collected. Rifampicin plus fusidic acid was the most frequently used regimen (24 (65%) out of 37 patients), with an overall success rate of 79% (19 out of 24 patients). Eradication failure was more likely in patients with an additional MRSA-positive peripheral screening swab (p=0.03) and was associated with worse survival (p=0.04). Our results demonstrate the feasibility and clinical benefits of MRSA eradication. As peripheral colonisation was associated with lower eradication success, strategies combining systemic and topical treatments should be considered to optimise outcomes in CF patients.

Original languageEnglish
Article number00064-2015
JournalERJ Open Research
Issue number1
Publication statusPublished - 31 Mar 2016

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis'. Together they form a unique fingerprint.

Cite this